Business India ×
  Magazine:
Cover Feature

Published on: July 26, 2020, 10:01 p.m.
"We have five different vaccines undergoing trials"
  • Photo credit: Umesh Goswami

By Sumit Ghoshal. Contributing Editor, Business India

Q Kindly elaborate on the nature of your agreement with AstraZeneca. Is it with the global company or with the Indian subsidiary? Also, is AZ going to provide the technology for the Covid-19, or is Serum Institute a participant in the development research as well?

A Serum Institute of India has entered into a manufacturing partnership with AstraZeneca (Global) to produce and supply the Oxford vaccine candidate for Covid-19 across India and other low-and-middle-income countries (GAVI countries). Our facilities are well-equipped with the latest technology to develop and commence mass-production of the vaccine after getting regulatory approvals. 

Q You have mentioned that clinical trials for the Oxford-AZ vaccine would involve about 4,000-5,000 subjects. Which phase would these trials belong to – Phase 1 or 2? Is it correct to say that many of these subjects are employees of Serum Institute?

A We expect to commence Phase 3 human trials in India around August 2020, with 4,000-5,000 patients in India. We can confirm the details of the trials once we receive all the requisite approvals. We plan to conduct these trials in Mumbai and Pune, as they are the main hotspots. I am sure that we will get enough people to volunteer for the trials. 

Q In a recent TV interview, you are reported to have said that you have about five different agreements underway. Are all these for Covid-19 vaccines or for different diseases? And how would these help to reduce the potential losses in case the Oxford-AZ vaccine does not work out in the end? 

A The world needs an immunogenic vaccine to fight the virus and we are committed to bring one at the earliest. Given the severity and the urgency of the situation, we did not want to rely on just one candidate. In case, one candidate didn’t work, we wanted to have an alternate course of action. This is why we have tied up with five vaccine candidates against Covid-19. Two of which are our own candidates. We hope to announce the availability of our own vaccines by the end of 2021. As per our associations, we are to manufacture and distribute the Novavax candidate across GAVI nations. The Codagenix vaccine is expected to progress soon and we have a global manufacturing and supply association with them. We have also tied up with a company for an mRNA vaccine candidate and hope to announce that soon. 

Q Recently, Serum announced the DCGI approval for a pneumococcal conjugate vaccine that had been under clinical trials since 2013. Where does this fit into Serum’s overall scheme of things?

A Serum Institute had first obtained the approval of DCGI to conduct clinical trials in Phases I, II and III. Post reviewing the clinical data, the company got permission to manufacture its own indigenously developed pneumococcal vaccine. This is a pneumococcal polysaccharide conjugate vaccine that took five years to develop and conduct multi-centric global trials before it was licensed. The vaccine is used for active immunisation against invasive disease and pneumonia caused by Streptococcus pneumoniae in infants. 

Q What is the total number of vaccine doses that Serum produces each year? And if you plan to produce 300-400 million doses of the Covid-19 vaccine in 2021, how much of the company’s resources would this demand?

A On average, Serum Institute of India produces and sells (more than 1.5 billion doses) globally which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Presently, keeping in mind the pandemic situation, we have dedicated two of our facilities to produce millions of doses for Covid-19 vaccine, while withholding vast production of other products.

Q You have spoken about a possible $200 million hit in the event that the Oxford-AZ vaccine fails the final tests. Does this include the peripheral and preparatory expenses as well as the budget outlay on the clinical trials?

A Yes, we will incur losses in case the vaccine fails. It includes the peripheral and preparatory expenses of raw materials, and human resources. We are yet to begin with the clinical trials. We will be able to comment on this once we have all the requisite licensure trials approvals.

Don't miss this

Cover Feature

The great Indian infra dream

National Infrastructure Pipeline (NIP) offers post-Covid-19 opportunity for economic revival. But is the government up to it?

Feature

Electrifying India’s vehicles

With a shortage of fossil fuels and tougher emission norms, cars driven by electricity could be the new normal in decades

Focus

Exports show formidable revival signs

It is time for India to resolve issues and take a fresh stance in the international market

Corporate Report

The Parliament project pushes Tata Projects higher

The company has emerged as one of India’s leading infrastructure companies

Our letter to you, once a week.
Register with The CSR Weekly for free!

E-MAGAZINE
The great Indian infrastructure dream
Cyrus-Mistry-the-$20-billion-question
Man of Steel
FROM THIS ISSUE

Government

Corporate Report

Corporate Report

F&B

Corporate Report

States

Social Responsibility

Mobility

HeroMotoCorp donates motorcycle ambulances

Published on Oct. 30, 2020, 11:05 a.m.

Continuing its assistance in fighting Covid-19, the two-wheeler major donates specially modified First Responder Vehicles to Uttarakhand

Sanitation

‘Hyundai Cares’ continues to work for health, education and a clean India

Published on Oct. 28, 2020, 2:44 p.m.

The car giant has a triad of schemes to distribute masks and education devices as well as a rural sanitisation programme

Innovation

Infotech company KPIT works with MAGIC in Aurangabad

Published on Oct. 21, 2020, 4:37 p.m.

The Marathwada Accelerator for Growth and Incubation Council is partnering with KPIT Sparkle 2021 to support student innovators

Social Inclusion

CRI Pumps in Coimbatore has a host of socially responsible programmes

Published on Oct. 21, 2020, 4:37 p.m.

The company works with Coimbatore Corporation and leading NGOs to organise cleaning drives and awareness programmes

Climate Change

Land Use

Building resilience for an urbanising India

Published on Oct. 30, 2020, 10:25 a.m.

Climate change with its range of impact on regions and geographies needs the participation of communities

Green Buildings

How green is your storage? Ask CII-IGBC

Published on Oct. 30, 2020, 10:09 a.m.

The industry body’s new initiative will help logistics systems in India to save energy and water as well as improving health

Waste Management

GD Environmental sees an opportunity in medical waste

Published on Oct. 21, 2020, 5:34 p.m.

The company sees strong opportunities in fundamentally shifting the costs and process of waste management

Energy

Energy storage leaders call for policy measures to create Atmanirbhar Bharat

Published on Oct. 8, 2020, 11:48 a.m.

Global thought leaders and policymakers discussed the issue to mark World Energy Storage Day recently

Stay ahead of the times.
Register with The Climate Change Weekly for free!